Microbot Medical presented positive data from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System at the Society of Interventional Radiology annual meeting. The trial, conducted at three leading U.S. medical centers, demonstrated 100% successful robotic navigation in 20 cases and a 92% reduction in radiation exposure with no adverse events. The system received 100% physician satisfaction.
This successful trial represents a significant advancement in endovascular surgery. The demonstrated reduction in radiation exposure offers substantial benefits for both patients and healthcare professionals, minimizing long-term health risks associated with repeated radiation exposure during complex procedures. The 100% success rate and high physician satisfaction suggest that the LIBERTY® system is a promising and effective tool with the potential to improve procedural outcomes. This data could encourage wider adoption of robotic systems in endovascular procedures, marking a shift towards safer and more precise interventions.
The ACCESS-PVI trial achieved its primary endpoint of successful robotic navigation in all cases. The study showcased a remarkable 92% reduction in radiation exposure compared to traditional methods. Notably, the median robotic navigation time to the target area was only three minutes, highlighting the system’s efficiency. No adverse device events were reported, reinforcing the system’s safety profile.
The positive results from the ACCESS-PVI trial pave the way for Microbot Medical to pursue FDA 510(k) clearance and commercialization of the LIBERTY® system. Pending regulatory approval, this technology has the potential to transform endovascular surgery, offering a less invasive and more precise approach with reduced radiation exposure for a wide range of procedures. This could lead to improved patient outcomes and potentially reduce healthcare costs associated with complications and longer recovery times. The technology’s disposable nature also addresses a key barrier to robotic surgery adoption by eliminating the costs and complexities associated with reusable robotic systems.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
